JonesResearch initiated coverage of Janux Therapeutics with a Buy rating and $70 price target. Janux is a clinical stage oncology company, potentially in the lead position with T cell engaging assets and masking technology, the analyst tells investors in a research note. The firm sees Janux as attractively priced and says it could get acquired with an additional 10%-15% premium to the current valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Short Report: Bears reduce exposure to Kohlâs as stock momentum fizzles
- Janux Therapeutics trading resumes
- Janux weighing sale after attracting interest, Bloomberg reports
- Janux jumps 9% to $43.75 after Bloomberg report of takeover interest
- Janux Therapeutics exploring sale after attractive interest, Bloomberg says
